Cannabix is developing Marijuana Breathalyzer devices to give law enforcement and employers a tool to enhance public safety
VANCOUVER, British Columbia, April 19, 2021 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer devices for law enforcement and the workplace, reports that it has received a notice of allowance from the Canadian Intellectual Property Office (CIPO) for its 2015 licensed patent application, No. 2887841 entitled, “Cannabis Drug Detection Device”. The Company has been pursuing this original patent application since its filing on April 16, 2015. It should be noted that a notice of allowance from the CIPO does not constitute a grant of patent. The Company will report on future material developments regarding its “Cannabis Drug Detection Device” patent application with CIPO in due course.
Cannabix Technologies is on the forefront in research and development to create point-of-care breath testing technologies for the detection of ∆9-tetrahydrocannabinol (“THC”) – the psychoactive component of marijuana that causes impairment.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana breathalyzer technologies for law enforcement and the workplace. Cannabix is working to develop drug-screening devices that will detect THC- the psychoactive component of marijuana that causes impairment using breath samples. Breath testing for THC would allow employers and law enforcement to identify recent marijuana use that better aligns with impairment.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing “patent pending” technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
At #SNMMI24, GE HealthCare expands its technology with the addition of a MINItrace Magni,i designed…
NEWPORT BEACH, CA / ACCESSWIRE / June 7, 2024 / Dr. Garrett Wirth, renowned plastic…
Marion, North Carolina--(Newsfile Corp. - June 7, 2024) - Greene Concepts Inc. (OTC Pink: INKW)…
A new study from deCODE genetics uses pedigrees and sequence data from 64,806 Icelanders to…
TEMPE, Ariz., June 7, 2024 /PRNewswire/ -- Economic activity in the hospital subsector grew in May for…
LANSING, Mich., June 7, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG), an innovative leader in…